SYGGF - Synairgen looking beyond COVID in fight against respiratory illness
(NewsDirect)
Synairgen PLC (AIM:SNG, OTC:SYGGF) chiefexecutive Richard Marsden speaks to Thomas Warner from ProactiveLondon about the company's ongoing efforts to develop what hedescribes as a "drug to help patients handle respiratoryviruses."
He explains that workon the drug long predates the COVID pandemic and has intensifiedsince, but is careful to emphasise that the intention of Synairgen isto develop a respiratory drug that can be of use to patients withother respiratory conditions as well. He notes the importance oflooking beyond COVID-19, given the unpredictability of its mediapresence and its potential long-term existence alongside otherviruses.
Marsden discusses theirpast Sprinter trial and the need for targeted future clinical trials.Utilising technologies and data that emerged during the pandemic,Synairgen plans to identify patients most likely to deteriorate due tothe virus. This strategic approach aims to conduct faster trials witha higher chance of success.
Marsdenconcluded that as they refine patient selection for upcoming trials,they'll announce results and commence the next clinical trialphase.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.